肺癌化学療法におけるデキサメタゾン8mgと16mgの急性及び遅延性悪心・嘔吐に対する効果の比較検討

概要

論文の詳細を見る
We performed a retrospective study that compared the efficacy and safety of dexamethasone (DEX) 8mg with DEX 16mg in cases of acute and delayed emesis induced by cisplatin (CDDP) chemotherapy in patients with lung cancer. Sixty-eight lung cancer patients treated with combination cisplatin, ifosfamide, and irinotecan therapy were studied. The DEX 8mg group and the DEX 16mg group received DEX intravenous injection 30min prior to CDDP. All patients then received a 5-HT_3 antagonist intravenous injection 30min before CDDP. Protection from acute nausea (day 1) was significantly superior in the DEX 16mg group compared with the DEX 8mg group (DEX 8mg, 76.5%; DEX 16mg, 100%). Protection from delayed emesis (day 1) was significantly superior in the DEX 16mg group compared with the DEX 8mg group. There was no reported severe nausea (grade 3) and vomiting (grade 2) in the DEX 16mg group. Furthermore, perphenazine hydrochloride for use as rescue medication was required by significantly fewer patients in the DEX 16mg group than in the DEX 8mg group (DEX 8mg, 41.2%; DEX 16mg, 0%). Adverse effects were observed in 10 cases (nine reports of generalized fatigability, two of headache) in the DEX 8mg group and in 16 cases (11 reports of generalized fatigability, one of pruritus) in the DEX 16mg group. However, because the symptoms were all mild, we did not consider that there was any safety problem. In conclusion, DEX 16mg is a clinically useful treatment for acute and delayed emesis induced by cisplatin-induced chemotherapy in patients with lung cancer.
社団法人日本薬学会の論文
2006-01-01

肺癌化学療法におけるデキサメタゾン8mgと16mgの急性及び遅延性悪心・嘔吐に対する効果の比較検討

スポンサーリンク

概要

著者

関連論文

スポンサーリンク